CL2015001536A1 - Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras. - Google Patents
Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras.Info
- Publication number
- CL2015001536A1 CL2015001536A1 CL2015001536A CL2015001536A CL2015001536A1 CL 2015001536 A1 CL2015001536 A1 CL 2015001536A1 CL 2015001536 A CL2015001536 A CL 2015001536A CL 2015001536 A CL2015001536 A CL 2015001536A CL 2015001536 A1 CL2015001536 A1 CL 2015001536A1
- Authority
- CL
- Chile
- Prior art keywords
- prophylaxis
- atherosclerosis
- pain
- pyridine
- stroke
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 206010012689 Diabetic retinopathy Diseases 0.000 title 1
- 208000002193 Pain Diseases 0.000 title 1
- 208000006011 Stroke Diseases 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 title 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196022 | 2012-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001536A1 true CL2015001536A1 (es) | 2015-10-23 |
Family
ID=47290804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001536A CL2015001536A1 (es) | 2012-12-07 | 2015-06-05 | Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras. |
Country Status (33)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105143220B (zh) | 2013-03-07 | 2018-06-22 | 豪夫迈·罗氏有限公司 | 吡唑衍生物 |
| PE20151559A1 (es) | 2013-03-26 | 2015-11-05 | Hoffmann La Roche | Nuevos derivados de piridina |
| HRP20181141T1 (hr) | 2013-05-02 | 2018-09-21 | F. Hoffmann - La Roche Ag | Derivati purina kao agonisti cb2 receptora |
| BR112015027394A8 (pt) | 2013-05-02 | 2018-01-30 | Hoffmann La Roche | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 |
| AU2014317229B2 (en) | 2013-09-06 | 2018-11-08 | F. Hoffmann-La Roche Ag | Novel triazolo(4,5-d)pyrimidine derivatives |
| AU2015239537B2 (en) * | 2014-04-04 | 2019-04-04 | Eidgenoessische Technische Hochschule Zuerich | 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists |
| EP3156397B1 (en) | 2014-06-13 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2017097732A1 (en) * | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Phenyl derivatives as cannabinoid receptor 2 agonists |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| AR112199A1 (es) | 2017-06-20 | 2019-10-02 | Hoffmann La Roche | Derivados de piridina como agonistas inversos del receptor cannabinoide 2 |
| JP2021521228A (ja) * | 2018-04-18 | 2021-08-26 | ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ | Ｄ−グルカロ−６，３−ラクトンモノエステル及びその製造方法 |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| EP3814337B1 (en) * | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| MX2020012760A (es) | 2018-06-27 | 2021-03-25 | Hoffmann La Roche | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. |
| EP3814328B1 (en) * | 2018-06-27 | 2026-03-11 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2 |
| CN114502538A (zh) * | 2019-09-30 | 2022-05-13 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉 |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| EP4326257A4 (en) * | 2021-04-19 | 2025-03-12 | ChemoCentryx, Inc. | AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008040649A2 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
-
2013
- 2013-12-02 LT LTEP13799520.5T patent/LT2928881T/lt unknown
- 2013-12-02 RS RS20180493A patent/RS57143B1/sr unknown
- 2013-12-02 SG SG10201800170YA patent/SG10201800170YA/en unknown
- 2013-12-02 EP EP13799520.5A patent/EP2928881B1/en not_active Not-in-force
- 2013-12-02 WO PCT/EP2013/075225 patent/WO2014086705A1/en not_active Ceased
- 2013-12-02 JP JP2015545757A patent/JP6426618B2/ja not_active Expired - Fee Related
- 2013-12-02 CN CN201380063475.9A patent/CN104837831B/zh not_active Expired - Fee Related
- 2013-12-02 SG SG11201504416XA patent/SG11201504416XA/en unknown
- 2013-12-02 UA UAA201506688A patent/UA114656C2/uk unknown
- 2013-12-02 PT PT137995205T patent/PT2928881T/pt unknown
- 2013-12-02 MA MA38239A patent/MA38239A1/fr unknown
- 2013-12-02 BR BR112015012919A patent/BR112015012919A2/pt not_active Application Discontinuation
- 2013-12-02 PL PL13799520T patent/PL2928881T3/pl unknown
- 2013-12-02 ES ES13799520.5T patent/ES2668690T3/es active Active
- 2013-12-02 CA CA2890100A patent/CA2890100A1/en not_active Abandoned
- 2013-12-02 CN CN201710932324.2A patent/CN107674061A/zh active Pending
- 2013-12-02 NO NO13799520A patent/NO2928881T3/no unknown
- 2013-12-02 EP EP18154216.8A patent/EP3357918A1/en not_active Withdrawn
- 2013-12-02 AU AU2013354278A patent/AU2013354278B2/en not_active Ceased
- 2013-12-02 DK DK13799520.5T patent/DK2928881T3/en active
- 2013-12-02 MX MX2015007155A patent/MX2015007155A/es unknown
- 2013-12-02 KR KR1020157017889A patent/KR20150092282A/ko not_active Withdrawn
- 2013-12-02 PE PE2015000744A patent/PE20151025A1/es not_active Application Discontinuation
- 2013-12-02 EA EA201591064A patent/EA026669B1/ru not_active IP Right Cessation
- 2013-12-02 US US14/648,431 patent/US9522886B2/en not_active Expired - Fee Related
- 2013-12-02 HU HUE13799520A patent/HUE036911T2/hu unknown
- 2013-12-02 SI SI201331023T patent/SI2928881T1/en unknown
- 2013-12-02 HR HRP20180672TT patent/HRP20180672T1/hr unknown
- 2013-12-06 AR ARP130104545A patent/AR093843A1/es unknown
- 2013-12-06 TW TW102144952A patent/TWI600645B/zh not_active IP Right Cessation
-
2015
- 2015-04-29 CO CO15097806A patent/CO7350620A2/es unknown
- 2015-05-12 CR CR20150250A patent/CR20150250A/es unknown
- 2015-05-15 PH PH12015501083A patent/PH12015501083B1/en unknown
- 2015-05-28 IL IL239075A patent/IL239075B/en not_active IP Right Cessation
- 2015-06-03 ZA ZA2015/03969A patent/ZA201503969B/en unknown
- 2015-06-05 CL CL2015001536A patent/CL2015001536A1/es unknown
-
2017
- 2017-12-20 AU AU2017279648A patent/AU2017279648A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001537A1 (es) | Compuestos derivados de piridin-2-amidas agonistas cb2; proceso de sintesis; composicion farmaceutica; uso en el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras. | |
| CL2015001538A1 (es) | Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras. | |
| CL2014001174A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades. | |
| CL2015001802A1 (es) | Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros | |
| CL2015002628A1 (es) | Compuestos de heteroarilo y sus usos. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2011000978A1 (es) | Compuestos derivados de fenil-amida o piridil-amida, agonistas de gpbar1; proceso de preparacion; composicion farmaceutica; y su uso en diabetes, isquemia, obesidad, dislipidemia, entre otras. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| CL2015001318A1 (es) | Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras. | |
| CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| CL2014002756A1 (es) | Compuestos derivados de 1,4-benzotiazepina; composición farmacéutica que lo comprende; uso para tratar afecciones relacionadas con función anormal de receptores de rianodina; y método de preparación del compuesto. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
| MX2017014237A (es) | Reacciones de macro-ciclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina. | |
| CO6880069A2 (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
| MX378866B (es) | Composiciones de azucar para la formacion de comprimidos por compresion directa. | |
| CL2013003686A1 (es) | Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña. | |
| MX373268B (es) | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. | |
| CR20160460A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| CL2014001309A1 (es) | Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras. | |
| EA201692037A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| CL2015000818A1 (es) | Compuestos derivados de n-prop-2-inil carboxamida, antagonistas del receptor transitorio potencial de la subfamilia 1, miembro 1 (trpa1); composicion farmaceutica que los comprende; y metodo para el tratamiento del dolor neuropatico, dolor por polineuropatia diabetica, dolor postoperatorio y dolor por cancer, entre otros. |